Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8+ T cell infiltration, suggesting a potential combination strategy to improve immunotherapy efficacy. The gene discussed is CD8A; the disease is neoplasm.